Gazette Tracker
Gazette Tracker

Core Purpose

The National Pharmaceutical Pricing Authority fixes the retail prices for 41 specific pharmaceutical formulations under the Drugs (Prices Control) Order, 2013.

Detailed Summary

The Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals, through the National Pharmaceutical Pricing Authority (NPPA), issued Order S.O. 2469(E) on June 3, 2025, exercising powers conferred by paragraphs 5, 11, and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated May 30, 2013, and S. O. 5249(E) dated November 11, 2022. This order fixes the retail prices, exclusive of Goods and Services Tax, for 41 pharmaceutical formulations. Noteworthy examples include Alginate Raft-Forming Oral Suspension at Rs. 0.93 per ml, Atorvastatin & Ezetimibe Tablets at Rs. 19.66 and Rs. 54.29 per tablet, Ceftriaxone, Sulbactam & Disodium Edetate Powder for solution for Infusion at Rs. 515.57 per vial, and various combinations of Empagliflozin, Metformin Hydrochloride, Linagliptin, Sitagliptin, and Glimepiride, with prices ranging from Rs. 0.23 per ml to Rs. 515.57 per vial. Manufacturers of these 'new drugs' (as defined under paragraph 2(1)(u) of DPCO, 2013) must adhere to these fixed prices, issue a price list in Form-V to NPPA via IPDMS, and provide copies to State Drug Controllers and dealers, in accordance with paragraph 24 of the DPCO, 2013. Retailers and dealers are mandated by para 24(4) of DPCO 2013 to conspicuously display these price lists. The specified retail prices are applicable only to manufacturers/marketers who have applied for price fixation/revision by submitting Form-I and who fulfill all applicable statutory requirements, including manufacturing license permissions. Non-compliance will lead to liability for depositing overcharged amounts with interest under the provisions of the DPCO, 2013, read with the Essential Commodities Act, 1955. This order supersedes any previous price orders for the listed formulations from the specified manufacturers and marketing companies.

Full Text

REGD. No. D. L.-33004/99 The Gazette of India CG-DL-E-03062025-263568 EXTRAORDINARY PART II—Section 3—Sub-section (ii) PUBLISHED BY AUTHORITY No. 2410] NEW DELHI, TUESDAY, JUNE 3, 2025/JYAISTHA 13, 1947 MINISTRY OF CHEMICALS AND FERTILIZERS (Department of Pharmaceuticals) (NATIONAL PHARMACEUTICAL PRICING AUTHORITY) ORDER New Delhi, the 3rd June, 2025 S.O. 2469(E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof; TABLE +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | SI. | Medicines | Strength | Unit | Manufacturer & | Retail | | No. | | | | Marketing Company | Price | | | | | | | (Rs.) | +=====+==================================+=====================================+==========+=======================================+=============+ | (1) | (2) | (3) | (4) | (5) | (6) | +=====+==================================+=====================================+==========+=======================================+=============+ | | Alginate Raft- | Each 5 ml contains: | | M/s Akums Drugs & | | | 1 | Forming Oral | Sodium Alginate IP 250 mg | 1 ml | Pharmaceuticals Ltd./ | 0.93 | | | Suspension | Sodium Bicarbonate IP 133.5 mg | | M/s Apex Laboratories | | | | | Calcium Carbonate IP 80 mg | | Pvt. Ltd. | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Atorvastatin & | Each film coated tablet contains: | | M/s Safetab Life Science/ | | | 2 | Ezetimibe Tablets | Atorvastatin Calcium IP | 1 Tablet | M/s Ajanta Pharma Ltd. | 19.66 | | | | equivalent to Atorvastatin 10mg | | | | | | | Ezetimibe IP 10mg | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Atorvastatin & | Each film coated tablet contains: | | M/s Windlas Biotech | | | 3 | Ezetimibe Tablets | Atorvastatin Calcium IP | 1 Tablet | Ltd./ | 54.29 | | | | equivalent to Atorvastatin 80 mg | | M/s Zydus Healthcare | | | | | Ezetimibe IP 10mg | | Ltd. | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Ceftriaxone, | Each vial contains: Ceftriaxone | | M/s BDR Pharma- | | | | Sulbactam & | Sodium IP eq. to Ceftriaxone | | ceuticals International | | | 4 | Disodium Edetate | 1000 mg Disodium Edetate IP 37 | 1 vial | Pvt. Ltd./ M/S Glenmark | 515.57 | | | Powder for solution | mg Sulbactam Sodium IP eq. | | Pharma-ceuticals Ltd. | | | | for Infusion | Sulbactam 500 mg | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Cefuroxime & | Each film coated tablet contains: | | M/s Supermax Drugs & | | | 5 | Potassium | Cefuroxime Axetil IP eq. to | | Pharmaceuticals Pvt. Ltd. | 60.62 | | | Clavulanate Tablets | Cefuroxime 500 mg | 1 Tablet | / M/s Profic Organic Ltd. | | | | | Potassium Clavulanate Diluted IP | | | | | | | eq. to Clavulanic Acid 125 mg | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Cholecalciferol | Each ml of Suspension contains: | | M/s Stedman | | | 6 | Oral Drops | Vitamin D3 IP 800 IU | 1 ml | Pharmaceuticals Pvt. Ltd. | 4.76 | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Clindamycin & | Clindamycin Phosphate IP eq. to | | M/s Skymap | | | 7 | Nicotinamide gel | Clindamycin 1.00% w/w | 1 gm | Pharmaceuticals Pvt. | 7.24 | | | | Nicotinamide IP 4.00% w/w | | Ltd./ | | | | | | | M/s German Remedies | | | | | | | Pharmaceuticals Pvt. Ltd. | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Iron, Folic Acid & | Each 5 ml contains: | | M/s East African (I) | | | 8 | Cyanocobalamin | Ferric Ammonium Citrate IP | 1 ml | Overseas / | 0.23 | | | Syrup | 110 mg | | M/s Mankind Prime Labs | | | | | Folic Acid IP 1.5 mg | | Pvt. Ltd. | | | | | Cyanocobalamin IP 15 mcg | | | | | | | Sorbitol (70%) (Non- | | | | | | | Crystallising) | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Melatonin & | Each film coated tablet contains: | | M/s Windlas Biotech | | | 9 | Zolpidem Tartrate | Melatonin BP 3 mg | 1 Tablet | Ltd./ | 6.62 | | | Tablets | Zolpidem Tartrate IP 5 mg | | M/s Ipca Laboratories | | | | | | | Ltd. | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Melatonin & | Each film coated tablet contains: | | M/s Windlas Biotech | | | 10 | Zolpidem Tartrate | Melatonin BP 3 mg | 1 Tablet | Ltd./ | 8.73 | | | Tablets | Zolpidem Tartrate IP 10 mg | | M/s Ipca Laboratories | | | | | | | Ltd. | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Polmacoxib & | Each uncoated tablet contains: | | M/s Hetero Labs Ltd./ | | | 11 | Paracetamol | Polmacoxib IH 2 mg | 1 Tablet | M/s Zuventus Healthcare | 15.39 | | | Tablets | Paracetamol IP 325 mg | | Ltd. | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin & | Each film coated bilayered tablet | | M/s Pure and Cure | | | 12 | Metformin | contains: | 1 Tablet | Healthcare Pvt. Ltd./ | 9.90 | | | Hydrochloride | Empagliflozin 10mg | | M/s Blue Cross | | | | (ER) Tablets | Metformin Hydrochloride | | Laboratories Pvt. Ltd. | | | | | 1000mg | | | | | | | (as extended release) | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin & | Each film coated tablet contains: | | M/s Unison | | | 13 | Metformin | Empagliflozin 12.5 mg | 1 Tablet | Pharmaceuticals Pvt. Ltd. | 18.10 | | | Hydrochloride | Metformin Hydrochloride IP 500 | | | | | | Tablets | mg | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin & | Each film coated tablet contains: | | M/s Exemed | | | 14 | Metformin | Empagliflozin 12.5 mg | 1 Tablet | Pharmaceuticals/ | 18.10 | | | Hydrochloride | Metformin Hydrochloride IP 500 | | M/s Zydus Healthcare | | | | Tablets | mg | | Ltd. | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin & | Each film coated tablet contains: | | M/s Unison | | | 15 | Metformin | Empagliflozin 12.5 mg | 1 Tablet | Pharmaceuticals Pvt. Ltd. | 19.01 | | | Hydrochloride | Metformin Hydrochloride IP 1000 | | | | | | Tablets | mg | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin & | Each film coated tablet contains: | | M/s MSN Laboratories | | | 16 | Metformin | Empagliflozin 12.5 mg | 1 Tablet | Pvt. Ltd. | 17.86 | | | Hydrochloride | Metformin Hydrochloride IP 1000 | | | | | | (ER) Tablets | mg (as Extended release) | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin & | Each film coated bilayered tablet | | M/s Pure and Cure | | | 17 | Metformin | contains: | 1 Tablet | Healthcare Pvt. Ltd./ | 11.70 | | | Hydrochloride | Empagliflozin 25 mg | | M/s Blue Cross | | | | (ER) Tablets | Metformin Hydrochloride IP | | Laboratories Pvt. Ltd. | | | | | 1000 mg (as extended release) | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin & | Each film coated tablet contains: | | M/s MSN Laboratories | | | 18 | Metformin | Empagliflozin 25 mg | 1 Tablet | Pvt. Ltd. | 18.75 | | | Hydrochloride | Metformin Hydrochloride IP | | | | | | (ER) Tablets | 1000 mg (as Extended release) | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin, | Each film coated tablet contains: | | M/s Pure and Cure | | | 19 | Linagliptin & | Empagliflozin 10 mg | 1 Tablet | Healthcare Pvt. Ltd./ | 29.08 | | | Metformin | Linagliptin 5 mg | | M/s Zydus Healthcare | | | | Hydrochloride | Metformin Hydrochloride IP | | Ltd. | | | | (ER) Tablets | 1000 mg (as Extended Release) | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin, | Each film coated tablet contains: | | M/s Pure and Cure | | | 20 | Linagliptin & | Empagliflozin 10 mg, | 1 Tablet | Healthcare Pvt. Ltd./ | 29.08 | | | Metformin | Linagliptin 5 mg, | | M/s Cadila | | | | Hydrochloride | Metformin Hydrochloride IP 1000 | | Pharmaceuticals Ltd. | | | | (ER) Tablets | mg (as Extended Release) | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin, | Each film coated tablet contains: | | M/s Pure and Cure | | | 21 | Linagliptin & | Empagliflozin 10 mg, | 1 Tablet | Healthcare Pvt. Ltd./ | 29.08 | | | Metformin | Linagliptin 5 mg, | | M/s Glenmark | | | | Hydrochloride | Metformin Hydrochloride IP | | Pharmaceuticals Ltd. | | | | (ER) Tablets | 1000 mg (as Extended Release) | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin, | Each film coated tablet contains: | | M/s Pure and Cure | | | 22 | Linagliptin & | Empagliflozin 10 mg, | 1 Tablet | Healthcare Pvt. Ltd./ | 28.57 | | | Metformin | Linagliptin 5 mg, | | M/s Alkem Laboratories | | | | Hydrochloride | Metformin Hydrochloride IP | | Ltd. | | | | (ER) Tablets | 1000 mg (as Extended Release) | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin, | Each film coated tablet contains: | | M/s Pure and Cure | | | 23 | Linagliptin & | Empagliflozin 10 mg, | 1 Tablet | Healthcare Pvt. Ltd./ | 17.50 | | | Metformin | Linagliptin 5 mg, | | M/s Torrent | | | | Hydrochloride | Metformin Hydrochloride IP | | Pharmaceuticals Ltd. | | | | (ER) Tablets | 1000 mg (as Extended Release) | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin, | Each film coated tablet contains: | | M/s Pure and Cure | | | 24 | Linagliptin & | Empagliflozin 25 mg, | 1 Tablet | Healthcare Pvt. Ltd./ | 33.13 | | | Metformin | Linagliptin 5 mg, | | M/s Zydus Healthcare | | | | Hydrochloride | Metformin Hydrochloride IP 1000 | | Ltd. | | | | (ER) Tablets | mg (as Extended Release) | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin, | Each film coated tablet contains: | | M/s Pure and Cure | | | 25 | Linagliptin & | Empagliflozin 25 mg, | 1 Tablet | Healthcare Pvt. Ltd./ | 32.43 | | | Metformin | Linagliptin 5 mg, | | M/s Cadila | | | | Hydrochloride | Metformin Hydrochloride IP | | Pharmaceuticals Ltd. | | | | (ER) Tablets | 1000 mg (as Extended Release) | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin, | Each film coated bilayer tablet | | M/s Exemed | | | 26 | Linagliptin & | contains: | 1 Tablet | Pharmaceuticals/ | 33.13 | | | Metformin | Empagliflozin 25 mg, | | M/s Emcure | | | | Hydrochloride | Linagliptin 5 mg, | | Pharmaceuticals Ltd. | | | | (ER) Tablets | Metformin Hydrochloride IP | | | | | | | 1000 mg (as Extended Release) | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin, | Each film coated tablet contains: | | M/s Pure and Cure | | | 27 | Linagliptin & | Empagliflozin 25 mg, | 1 Tablet | Healthcare Pvt. Ltd./ | 33.13 | | | Metformin | Linagliptin 5 mg, | | M/s Glenmark | | | | Hydrochloride | Metformin Hydrochloride IP | | Pharmaceuticals Ltd. | | | | (ER) Tablets | 1000 mg (as Extended Release) | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin, | Each film coated tablet contains: | | M/s Pure and Cure | | | 28 | Linagliptin & | Empagliflozin 25 mg, | 1 Tablet | Healthcare Pvt. Ltd./ | 30.36 | | | Metformin | Linagliptin 5 mg, | | M/s Alkem Laboratories | | | | Hydrochloride | Metformin Hydrochloride IP | | Ltd. | | | | (ER) Tablets | 1000 mg (as Extended Release) | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Empagliflozin, | Each film coated tablet contains: | | M/s Pure and Cure | | | 29 | Linagliptin & | Empagliflozin 25 mg, | 1 Tablet | Healthcare Pvt. Ltd./ | 19.50 | | | Metformin | Linagliptin 5 mg, | | M/s Torrent | | | | Hydrochloride | Metformin Hydrochloride IP | | Pharmaceuticals Ltd. | | | | (ER) Tablets | 1000 mg (as Extended Release) | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Sitagliptin, | Each film coated tablet contains: | | M/s Exemed | | | 30 | Glimepiride & | Sitagliptin Phosphate | 1 Tablet | Pharmaceuticals/ | 12.82 | | | Metformin | Monohydrate IP eq. to Sitagliptin | | M/s USV Private Ltd. | | | | Hydrochloride | 50 mg | | | | | | Tablets | Glimepiride IP 1 mg | | | | | | | Metformin Hydrochloride IP | | | | | | | 500 mg | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Sitagliptin, | Each film coated tablet contains: | | M/s Exemed | | | 31 | Glimepiride & | Sitagliptin Phosphate | 1 Tablet | Pharmaceuticals/ | 12.82 | | | Metformin | Monohydrate IP eq. to Sitagliptin | | M/s Emcure | | | | Hydrochloride | 50 mg | | Pharmaceuticals Ltd. | | | | Tablets | Glimepiride IP 1 mg | | | | | | | Metformin Hydrochloride IP | | | | | | | 500 mg | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Sitagliptin, | Each film coated tablet contains: | | M/s Exemed | | | 32 | Glimepiride & | Sitagliptin Phosphate | 1 Tablet | Pharmaceuticals/ | 12.82 | | | Metformin | Monohydrate IP eq. to Sitagliptin | | M/s Alkem Laboratories | | | | Hydrochloride | 50 mg | | Ltd. | | | | Tablets | Glimepiride IP 1 mg | | | | | | | Metformin Hydrochloride IP | | | | | | | 500 mg | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Sitagliptin, | Each film coated tablet contains: | | M/s Exemed | | | 33 | Glimepiride & | Sitagliptin Phosphate | 1 Tablet | Pharmaceuticals/ | 12.82 | | | Metformin | Monohydrate IP eq. to Sitagliptin | | M/s Dr. Reddys | | | | Hydrochloride | 50 mg | | Laboratories Ltd. | | | | Tablets | Glimepiride IP 1 mg | | | | | | | Metformin Hydrochloride IP | | | | | | | 500 mg | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Sitagliptin, | Each film coated tablet contains: | | M/s Exemed | | | 34 | Glimepiride & | Sitagliptin Phosphate | 1 Tablet | Pharmaceuticals/ | 12.82 | | | Metformin | Monohydrate IP eq. to Sitagliptin | | M/s Zydus Healthcare | | | | Hydrochloride | 50 mg | | Ltd. | | | | Tablets | Glimepiride IP 1 mg | | | | | | | Metformin Hydrochloride IP | | | | | | | 500 mg | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Sitagliptin, | Each film coated tablet contains: | | M/s Exemed | | | 35 | Glimepiride & | Sitagliptin Phosphate | 1 Tablet | Pharmaceuticals/ | 14.50 | | | Metformin | Monohydrate IP eq. to Sitagliptin | | M/s USV Private Ltd. | | | | Hydrochloride | 50 mg | | | | | | Tablets | Glimepiride IP 2 mg | | | | | | | Metformin Hydrochloride IP | | | | | | | 500 mg | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | 36 | Sitagliptin, | Each film coated tablet contains: | 1 Tablet | M/s Exemed | 14.50 | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Glimepiride & | Sitagliptin Phosphate | | Pharmaceuticals/ | | | 37 | Metformin | Monohydrate IP eq. to Sitagliptin | 1 Tablet | M/s Alkem Laboratories | 14.50 | | | Hydrochloride | 50 mg | | Ltd. | | | | Tablets | Glimepiride IP 2 mg | | | | | | | Metformin Hydrochloride | | | | | | | IP 500 mg | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Sitagliptin, | Each film coated tablet contains: | | M/s Exemed | | | 38 | Glimepiride & | Sitagliptin Phosphate | | Pharmaceuticals/ | 14.50 | | | Metformin | Monohydrate IP eq. to Sitagliptin | 1 Tablet | M/s Eris Lifesciences | | | | Hydrochloride | 50 mg | | Ltd. | | | | Tablets | Glimepiride IP 2 mg | | | | | | | Metformin Hydrochloride | | | | | | | IP 500 mg | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Sitagliptin, | Each film coated tablet contains: | | M/s Exemed | | | 39 | Glimepiride & | Sitagliptin Phosphate | | Pharmaceuticals/ | 14.50 | | | Metformin | Monohydrate IP eq. to Sitagliptin | 1 Tablet | M/s Dr. Reddys | | | | Hydrochloride | 50 mg | | Laboratories Ltd. | | | | Tablets | Glimepiride IP 2 mg | | | | | | | Metformin Hydrochloride | | | | | | | IP 500 mg | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Sitagliptin, | Each film coated tablet contains: | | M/s Exemed | | | 40 | Glimepiride & | Sitagliptin Phosphate | | Pharmaceuticals/ | 14.50 | | | Metformin | Monohydrate IP eq. to Sitagliptin | 1 Tablet | M/s Zydus Healthcare | | | | Hydrochloride | 50 mg | | Ltd. | | | | Tablets | Glimepiride IP 2 mg | | | | | | | Metformin Hydrochloride | | | | | | | IP 500 mg | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ | | Phenylephrine | Each 5 ml contains: | | M/s Vapi Care Pharma | | | 41 | Hydrochloride & | Phenylephrine Hydrochloride IP 5 | 1 ml | Pvt. Ltd. / | 1.01 | | | Chlorpheniramine | mg | | M/s Apex Laboratories | | | | Maleate Syrup | Chlorpheniramine Maleate | | Pvt. Ltd. | | | | | IP 2 mg | | | | +-----+----------------------------------+-------------------------------------+----------+---------------------------------------+-------------+ Note: (a) The manufacturer of above-mentioned formulations i.e., "new drug" under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove. (b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies. (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded. [PN/265/133/2025/F /F. No. 8(133)/2025/D.P./NPPA-Div.-II] MAHAVEER SAINI, Dy. Director Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064 and Published by the Controller of Publications, Delhi-110054.

Never miss important gazettes

Create a free account to save gazettes, add notes, and get email alerts for keywords you care about.

Sign Up Free